Naoyuki Kamatani
Director, Research Institute for Artificial Intelligence in Medicine, StaGen Co.

BIOGRAPHY

Currently, I am the Director, Research Institute for Artificial Intelligence in Medicine, StaGen Co. LTD and Director of StaGen Co. LTD. Until Dec. 2011, I served as the director of Center for Genomic Medicine (CGM), RIKEN, Japan. Before that, I had been the director and professor of Institute of Rheumatology, Tokyo Women’s Medical University where I served as a clinical rheumatologist. I have published more than 600 peer reviewed papers including 34 Nature or Nature Genetics papers. My publications cover a quite wide area of medicine and biology spanning from cancer genetics, nucleic acid metabolism, gout, rheumatic diseases, monogenic diseases, statistical genetics, statistics, bioinformatics and pharmacogenomics. Recently, I especially focus on genome-wide association studies (GWASs), new drug development based on genomics data and artificial intelligence.
I started to work for StaGen Co. Ltd, a private venture company that is dedicated to statistical and genetic data analysis, new drug development and artificial intelligence. Among a few drugs being developed by our company, ATP enhancer is the most important new drug. This drug is targeted at mitochondrial diseases and neurodegenerative disorders, and the efficacy and safety has been predicted by the data from many genetic diseases and GWASs.